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ABSTRACT  Gliotoxin (GT) is a mycotoxin produced by some species of asco-
mycete fungi including the opportunistic human pathogen Aspergillus fumiga-
tus. In order to produce GT the host organism needs to have evolved a self-
protection mechanism. GT contains a redox-cycling disulfide bridge that is 
important in mediating toxicity. Recently is has been demonstrated that A. 
fumigatus possesses a novel thiomethyltransferase protein called GtmA that 
has the ability to thiomethylate GT in vivo, which aids the organism in regulat-
ing GT biosynthesis. It has been suggested that thiomethylation of GT and 
similar sulfur-containing toxins may play a role in providing self-protection in 
host organisms. In this work we have engineered Saccharomyces cerevisiae, a 
GT-naïve organism, to express A. fumigatus GtmA. We demonstrate that 
GtmA can readily thiomethylate GT in yeast, which results in protection of the 
organism from exogenous GT. Our work has implications for understanding 
the evolution of GT self-protection mechanisms in organisms that are GT pro-
ducers and non-producers. 
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INTRODUCTION 
Gliotoxin (GT) is a fungal natural product with known anti-
biotic and antifungal properties and is biosynthesized by 
the opportunistic human pathogen, Aspergillus fumigatus, 
as well as by related ascomycetes [1-3]. Gliotoxin biosyn-
thesis is encoded by the gli gene cluster, which contains 13 
genes, and the function of most of these genes has now 
been elucidated [4]. Effectively, GT is the prototypic 
epipolythiodioxopiperazine (ETP) and is structurally and 
functionally related to a range of disulfide bridge-
containing non-ribosomal peptides including, amongst 
others, sporidesmin A and sirodesmin [2, 5]. GT is redox-
active; thus, cycling between the oxidized and reduced 
dithiol form (GT-(SH)2) can generate reactive oxygen spe-
cies, which have deleterious cellular effects. GT auto-
induces its own biosynthesis by activating and maintaining 
gli cluster expression [6]. In animal cells, GT can inactivate 
selected protein functionality by covalent interaction with 
protein thiols and also deplete cellular glutathione (GSH) [7, 
8]. Indeed, the cytotoxicity of GT is such that an inde-
pendently regulated gene within the gli cluster, gliT en-
codes GT oxidoreductase which recognizes GT-(SH)2 and 
catalyzes disulfide bridge closure and is essential in A. fu-
migatus for self-protection against exogenous GT [9-11]. 
GT is not biosynthesized by Saccharomyces cerevisiae 
(baker’s yeast). As a consequence, no endogenous protec-
tion system against GT exists in this species and S. cere-
visiae growth can be inhibited by exposure to GT [10, 12, 
13]. Expression of the A. fumigatus gliT-mediated self-
protection system in yeast has been shown to confer GT 
resistance, as has deletion of GSH1, responsible for GSH 
biosynthesis [10, 12]. Thus, by enabling disulfide bridge 
closure, preventing the GSH-mediated chemical reduction 
of exogenously-added GT to GT-(SH)2 or facilitating GT ef-
flux, the resistance of gliotoxin-naïve species to this redox-
active molecular species can be augmented. 
Gliotoxin bis-thiomethyltransferase (GtmA), the first bis 
thiomethyltransferase so far identified in any species, has 
recently been described in A. fumigatus and it has been 
shown to convert GT-(SH)2 to bisdethi-
obis(methylthio)gliotoxin (BmGT) (Figure 1) [14]. GtmA has 
also been contemporaneously characterized by others, 
where it is referred to as TmtA [15]. Interestingly, although 
GtmA is encoded outside the gli cluster, its expression is 
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induced by GT and it has been convincingly demonstrated 
to dissipate GT levels thereby attenuating gli cluster activi-
ty and concomitant GT biosynthesis [14]. In effect, GtmA 
appears to be the ‘off-switch’ for GT biosynthesis in A. fu-
migatus. Although an unidentified thiomethyltransferase 
has been shown to confer resistance to a bacterial non-
ribosomal peptide, holomycin, in Streptomyces clavivulgar-
is [16], gtmA deletion has effectively no impact on the sen-
sitivity of A. fumigatus to GT [14, 15]. 
Expression of gtmA in S. cerevisiae was therefore un-
dertaken to further investigate the functionality of this 
enzyme and to explore the hypothesis that, in the absence 
of concomitant GT biosynthesis and a gliT-mediated self-
protection system, GtmA could confer resistance to GT via 
BmGT formation. 
 
RESULTS AND DISCUSSION 
Expression of gtmA in yeast increases resistance to glio-
toxin 
While it has been clearly demonstrated that GliT provides 
the primary self-protection mechanism against GT in A. 
fumigatus [9, 10] and that the production of BmGT via 
GtmA is primarily linked to GT biosynthesis and regulation 
[14], given that the production of BmGT will nullify GT abil-
ity to redox cycle, we hypothesized that under certain bio-
logical conditions GtmA may be able to provide direct pro-
tection against GT toxicity. In previous work from our 
group and others [10, 12, 13] yeast was utilized as a tool to 
explore the in vivo effects of exposure to GT. Following 
cloning of gtmA under control of the constitutive SSA2 
promoter we demonstrated that gtmA is well expressed in 
yeast (Figure 2A). Growth of yeast is severely impaired on 
medium containing gliotoxin (8 and 16 μg/mL, respectively), 
but expression of gtmA in yeast provides protection 
against this cytotoxicity (Figure 2B). The level of protection 
provided to yeast by gtmA is more prominent than that 
provided by gliT expression (Figure 2B). Additionally, the 
level of protection provided when both gliT and gtmA are 
expressed in yeast is comparable to gtmA expression alone, 
which reflects the apparent more efficient GT detoxifica-
tion of GtmA compared to GliT when engineered in yeast. 
The expression of both gtmA and gliT does not allow yeast 
to efficiently grow on GT concentration above those used 
in this study [data not show]. Expression of the other me-
thyltransferases encoded within the gli-cluster, gliM and 
gliN [15], did not provide any protection in yeast against 
GT toxicity (data not shown). 
 
Expression of gtmA in yeast causes BmGT formation from 
exogenously-added gliotoxin 
Yeast does not contain an ortholog or homolog of A. fu-
migatus gtmA [14]. Consequently it is not surprising that 
we have never detected the production of BmGT in yeast 
following exposure to GT (Figure 3A and Figure 4A). The 
expression of gtmA in yeast provides this GT-naïve organ-
ism with the capability of converting GT to BmGT (Figure 
3B). The production of BmGT in yeast expressing gtmA is as 
a result of utilizing exogenous GT as a substrate (Figure 4B). 
 
Biological relevance for gliotoxin conversion to BmGT  
What is the biological significance for GT to BmGT conver-
 
 
FIGURE 1: Conversion of reduced GT to BmGT is mediated by 
GtmA protein. Reduced GT undergoes bis-thiomethylation via the 
action of GtmA protein and requires two molecules of SAM for 
the reaction to reach completion [14]. Consequently two mole-
cules of SAH are produced that re-enter the methyl-methionine 
cycle [17].  
 
FIGURE 2: Expression of gtmA in yeast 
protects against GT cytotoxicity. (A) RT-PCR 
demonstrating that gtmA mRNA is stably 
expressed in yeast. Yeast ERG9 mRNA pro-
duction is shown as a positive control. (B) 
Expression of A. fumigatus genes gtmA or 
gliT in yeast provides protection against GT 
cytotoxicity. 
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sion? The results we present here clearly show that GT 
conversion to BmGT protects against cytotoxicity and 
therefore appear to support the suggestion that thiometh-
ylation of GT is a protection mechanism, perhaps from 
exogenous and/or endogenously produced GT. However, 
to uncover the true biological relevance of GT to BmGT 
conversion we need to consider this reaction in the context  
of organisms that produce GT and those that do not. Re-
cent evidence has clearly shown that deletion of gtmA, and 
hence the removal of the ability to convert GT to BmGT, in 
A. fumigatus does not produce a GT-sensitive phenotype  
[14, 15]. This is due to the maintenance of a fully functional, 
primary detoxification system, GliT, in a gtmA deletion 
strain. Furthermore, it has recently been demonstrated 
that GliT functions in conjunction with the GT-specific 
transporter GliA to maintain intracellular GT at a level that 
is not toxic to the host cell [18]. The production of BmGT in 
A. fumigatus facilitates the secretion of this product in a 
GliA independent manner [18]. The secretion of BmGT 
from fungal cells most likely occurs through a non-specific 
mechanism as the molecule is efficiently secreted from 
yeast (this study) and from GliA-deficient A. fumigatus [18]. 
Thus the primary physiological relevance of converting GT 
to BmGT in GT-producing organisms appears to be as a 
negative regulator of GT biosynthesis, followed by secre-
tion of the inactive thiomethylated derivative [18]. Howev-
er, the in vivo consequence of GtmA activity, and conse-
quent BmGT production and secretion, will depend upon 
whether an organism is a GT producer or not. 
Here we clearly show that engineering a GT to BmGT 
conversion mechanism into a GT naïve organism, such as 
yeast, can provide efficient protection against exogenous 
GT (Figures 2, 3 and 4). The yeast genome does not encode 
for any GtmA homologs and does not endogenously con-
FIGURE 3: Detection 
and monitoring of GT 
and BmGT in yeast 
using mass spec-
trometry. (A) GT is 
readily detected in 
supernatants of yeast 
cells exposed to exog-
enous GT. (B) BmGT 
can only be detected 
in supernatants from 
yeast cells, which ex-
press gtmA, following 
exposure to exoge-
nous GT. 
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TABLE 1. Oligonucleotide primers used in this study. 
Primer Name Sequence 5’-3’ 
gtmA F AAAAAACATATGATGTCCAAGTCAGAC-TACATCCAG 
gtmA R AAAAAAGCATGCCTAGGGCTT-GAGGCCGGTTG 
ERG9 INTERAL F GACTTATTTGGCCGGTATCCACG 
ERG9 INTERNAL R CTCGACACAGCCACGCAAAGTCC 
gtmA RT-PCR F TCCAGCGTACTCAACCACAC 
gtmA RT-PCR R CGTCTGGAAAGCTCTGGAA 
 
vert GT to BmGT (Figure 3). Previous phylogenetic analysis 
identified organisms within the fungal kingdom that pos-
sess GtmA homologs [14] and the implications from the 
results of this study suggest that a GT non-producing or-
ganism that possesses a GtmA homolog may well utilize 
such a protein as a defense mechanism against GT expo-
sure. The absence of GT production in such organisms may 
suggest that from an evolutionary perspective such GtmA 
homologs may have evolved to carry out other GT-
independent functions in the cell and, if they possess the 
ability to produce BmGT, this may not be the primary func-
tion of the protein. Conversely, GT non-producing fungi 
may have retained GtmA homologs as a means of occupy-
ing the same habitats as GT-producing fungi. 
Moreover, the possibility does exist that GtmA homo-
logs in GT naïve fungi constitute an ancient ETP generic-
defense mechanism that has allowed the acquisition and 
development of the GT-producing gene cluster, or other 
ETP clusters. The evolution of the primary detoxification 
system involving GliT and GliA, in conjunction with the 
presence of GtmA, has then allowed for intricate systems-
level interactions to develop in organisms such as A. fu-
migatus, as recently shown for GT biosynthesis and inter-
play with the methyl/methionine cycle [18] and for regula-
tion of the gli-cluster itself [14]. Any effect upon GT sensi-
tivity of removing the GT to BmGT conversion system in A. 
fumigatus, or any GT-producing organism, may only be-
come apparent when undertaken along with the concomi-
tant abrogation of the primary GT-protection mechanism 
from the organism. Support for this hypothesis comes from 
the recent discovery that deletion of the gtmA homolog in 
GT-naïve Aspergillus niger results in sensitivity to exoge-
nously added GT [19]. 
 
 
 
MATERIALS AND METHODS 
Yeast strains, plasmids and genetic methods 
The S. cerevisiae strain used in this study was BY4741 (MATa; 
his3Δ 1; leu2Δ 0; met15Δ 0; ura3Δ 0) and was obtained from 
Euroscarf. All media used were as previously described by [20]. 
Cultures were grown at 30°C with shaking at 200 rpm. 
To observe the effects of gtmA expression in S. cerevisiae, 
gtmA was amplified from A. fumigatus cDNA (ATCC26933) 
using primers gtmA F and gtmA R (Table 1) and cloned into the 
yeast shuttle vector pC210 as previously described by [10]. 
Briefly, primers were designed that incorporated NdeI and 
SphI restriction sites. Following PCR amplification of the gtmA 
gene, digestion of the gtmA PCR product and of pC210 was 
carried out followed by ligation using T4 DNA ligases 
(Promega) according to manufacturer’s instructions to create 
pC210-gtmA. Cloning of the gtmA fragment and construct 
were confirmed using Sanger sequencing. 
Growth analysis was carried out by diluting an overnight 
culture of cells in fresh medium lacking leucine (-LEU) to an 
OD600 = 0.2 and incubated at 30°C shaking 200 rpm till an 
OD600 = 0.4 was reached. Cells were transferred to a microtiter 
FIGURE 4: Conversion of GT to BmGT over time in yeast expressing GtmA. (A) BmGT is not detected in supernatants of yeast cells exposed to 
exogenous GT over 3 h exposure. (B) BmGT is readily detected in supernatants from yeast cells expressing gtmA. Increased levels of BmGT can 
be detected over a 3-hour time period and correlate with a diminution GT levels. 
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plate and serially diluted. Cells were transferred to –LEU 
plates containing the desired concentration of GT (Sigma) 
using a replicator and incubated at 30°C for 48 h, with further 
monitoring at room temperature for 72 h. 
 
RT-PCR 
Total RNA was extracted from 5 mL cultures of the yeast 
strains grown overnight at 30°C shaking 200 rpm. RNA was 
extracted using the QIAGEN RNeasy plant mini kit as per man-
ufacturers’ guidelines. RNA was DNase treated using DNase I 
kit (Sigma-Aldrich), according to the manufacturer’s recom-
mendations. RNA concentrations were measured using a Nano 
Drop 1000 Spectrophotometer (Mason Technology). 
cDNA was synthesized using the qScriptTM cDNA Supermix 
(Quanta Biosciences) as per manufacturer’s instructions. Ac-
cuTaq LA polymerase (Sigma) was used to amplify a house-
keeping gene ERG9 as a control and the gene of interest gtmA. 
The primers used in RT-PCR reactions are listed in Table 1. PCR 
reactions were conducted in a PTC-200 Peltier Thermal Cycler 
(MJ Research) and the program consisted of 1 cycle of 95°C for 
5 min, 35 cycles of 95°C for 30 sec, 58°C for 30 sec and 68°C 
for 30 sec. Followed by a further cycle of 68°C for 10 min. 
 
Mass spectrometry detection of gliotoxin and bis-
methylgliotoxin 
GT uptake and BmGT conversion assays were carried out by 
diluting overnight cell cultures in -LEU medium to an OD600 = 
0.4 and incubation at 30°C shaking 200 rpm till an OD600 = 1.2 
was reached, followed by GT (5 μg/ml) addition and incuba-
tion for a further 3 h. Samples were taken every 30 min during 
the 3 h period, and were then centrifuged at 5,000 x g to ob-
tain the supernatant, which was then organically extracted 
using an equal volume of chloroform. Organic extracts were 
dried to completion under a vacuum and re-solubilized in 
methanol and analyzed by LC-MS (Agilent LC-MS system- 
Model 6340) as previously described [17]. 
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